

C014CIP/DIV1/US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Not Yet Assigned
Group Art Unit : 1641
Applicants : Michael J. Yellin et al.
Serial No. : 09/343,001
Filed : June 29, 1999
For : THERAPEUTIC APPLICATIONS FOR THE ANTI-T-BAM
(CD40-L) MONOCLONAL ANTIBODY 5C8 FOR THE
TREATMENT OF CHRONIC INFLAMMATORY DISEASE

January 18, 2000
New York, New York

Hon. Assistant Commissioner
for Patents
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), applicants
make of record, the following documents, copies of which are
submitted herewith:

PCT Patent Applications

PCT WO 98/30240, published July 16, 1998.
PCT WO 98/30241, published July 16, 1998.

OTHER REFERENCES

Press Release from Biogen website (www.prnewswire.com), "Biogen Says it Has Halted Several Trials of Anti-CD40 Ligand Monoclonal Antibody", October 21, 1999.

Press Release from Biogen website (www.prnewswire.com), "Biogen Says it Has Stopped Ongoing Trials of Anti-CD40 Ligand Monoclonal Antibody", November 2, 1999.

Written Opinion dated October 12, 1998 in PCT/US98/00573 (WO 98/30241).

January 8, 1999 Reply to Written Opinion dated October 12, 1998 in PCT/US98/00573 (WO 98/30241).

Written Opinion dated October 12, 1998 in PCT/US98/23482 (WO 98/30240).


January 8, 1999 Reply to Written Opinion dated October 12, 1998 in PCT/US98/23482 (WO 98/30240).

For the Examiner's convenience, the above-mentioned documents are listed on the accompanying Form PTO-1449.

Applicants respectfully request that the above-cited documents be (1) fully considered by the Examiner during the continued examination of this application and (2) printed on any patent issuing from this application. Applicants also request that a copy of the enclosed Form PTO-1449, duly initialed by the Examiner, be forwarded to the undersigned with the next communication.


Since this Statement is submitted more than three months from the application filing date and after the mailing date of the first Office Action, but before the mailing date of either a final action under 37 C.F.R. § 1.113, or a Notice of Allowance under 37 C.F.R. § 1.311, the Commissioner is hereby authorized to charge payment of the \$240.00 fee required pursuant to 37 C.F.R. § 1.17(p) to Deposit Account No. 06-1075*. The Commissioner is hereby authorized to charge payment of any additional fees required in connection with this Information Disclosure Statement to Deposit Account No. 06-1075*.

Respectfully submitted,



Margaret A. Pierri (Reg. No. 30,709)
Attorney for Applicants
Stanley D. Liang (Reg. No. 43,753)
Agent for Applicants
c/o FISH & NEAVE
1251 Avenue of the Americas
New York, New York 10020-1104
Tel.: (212) 596-9000

I hereby Certify that this
Correspondence is being
Deposited with the U.S.
Patent Office as First
Class Mail for the type
Advisory Office
Class of Mail No. 100
Patent
Washington, D.C. 20231 on

January 18, 2000
Charles J. Sullivan

Signature of Person Signing

* See accompanying Transmittal Letter, filed concurrently herewith in duplicate.

